Roche says that its experimental asthma drug, the IL-13 blocking antibody lebrikizumab, proved promising in a mid-stage clinical trial. Researchers said that the drug spurred in a "statistically significant increase in FEV1 (measure of lung function) in adults with asthma whose symptoms were inadequately controlled with inhaled corticosteroids." The results were published in the New England Journal of Medicine. Release